Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Radiopharm TheranosticsASX:RAD +11.11% Days Sales Outstanding is 376.04 as of Jun. 2025, which is 159% above its 10-year median of 144.99. The stock has 6 warning signs investors should review. Among 841 Biotechnology companies, Radiopharm Theranostics ranks worse than 78.36% on this metric.
Radiopharm Theranostics (ASX:RAD) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Radiopharm Theranostics Days Sales Outstanding Related Terms
Radiopharm Theranostics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Radiopharm Theranostics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radiopharm Theranostics Days Sales Outstanding Chart
ASX:RAD vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Radiopharm Theranostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radiopharm Theranostics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Radiopharm Theranostics's Days Sales Outstanding falls into.
Radiopharm Theranostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 376.04 mean?
Radiopharm Theranostics (ASX:RAD) has a Days Sales Outstanding of 376.04 as of Jun. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Radiopharm Theranostics and its competitors. This is 159% above median its historical median of 144.99. Over the past decade, Radiopharm Theranostics' Days Sales Outstanding has ranged from 100.63 to 2,271.11. According to the industry distribution chart, Radiopharm Theranostics ranks #659 out of 841 companies in the Biotechnology industry, placing it in the top 78.4%.
Is Radiopharm Theranostics' Days Sales Outstanding too high?
Radiopharm Theranostics' current Days Sales Outstanding of 376.04 is 159% above median its 10-year median of 144.99. Over the past 10 years, this metric has ranged from a low of 100.63 to a high of 2,271.11. The Biotechnology industry median Days Sales Outstanding is 68.94. Radiopharm Theranostics' value of 376.04 is 445.5% above this industry median. Based on the distribution chart, Radiopharm Theranostics ranks #659 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Radiopharm Theranostics' Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Radiopharm Theranostics ranks #659 out of 841 companies for Days Sales Outstanding. This places Radiopharm Theranostics in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. Radiopharm Theranostics' value of 376.04 is 445.5% above this benchmark. Historically, Radiopharm Theranostics' own Days Sales Outstanding has ranged from 100.63 to 2,271.11 over the past decade. While the company's 10-year median is 144.99 vs. the industry median of 68.94, Radiopharm Theranostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radiopharm Theranostics's current Days Sales Outstanding of 376.04 is 445.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Radiopharm Theranostics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radiopharm Theranostics's current Days Sales Outstanding is 376.04, which is 159% above median its own 10-year median of 144.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Based on GuruFocus' analysis, Radiopharm Theranostics (ASX:RAD) is currently considered Fairly Valued. The stock's GF Value™ is A$0.01, compared to a current price of A$0.01 — trading right at its estimated fair value. The current Days Sales Outstanding is 376.04, which is 159% above median its 10-year median of 144.99 and 445.5% above the Biotechnology industry median of 68.94. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Days Sales Outstanding is 376.04 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAD has been successfully added to your 
